These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 16248123

  • 1. Initial intravenous gamma-globulin treatment failure in Iranian children with Kawasaki disease.
    Kashef S, Safari M, Amin R.
    Kaohsiung J Med Sci; 2005 Sep; 21(9):401-4. PubMed ID: 16248123
    [Abstract] [Full Text] [Related]

  • 2. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
    Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
    [Abstract] [Full Text] [Related]

  • 3. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
    Khowsathit P, Hong-Hgam C, Khositseth A, Wanitkun S.
    J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
    [Abstract] [Full Text] [Related]

  • 4. [Effects of three intravenous gamma globulin regimens on Kawasaki disease and relevant coronary complication rates in pediatric patients: a comparative study].
    DU ZD, Zhao D, DU JB, Lu S, Yi JM, Hou AC, Zhou ZS, Ding GF, Beijing Kawasaki Disease Epidemilogy Study Grou.
    Zhonghua Yi Xue Za Zhi; 2007 Nov 27; 87(44):3119-21. PubMed ID: 18269869
    [Abstract] [Full Text] [Related]

  • 5. Immunoglobulin failure and retreatment in Kawasaki disease.
    Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C.
    Pediatr Cardiol; 2003 Nov 27; 24(2):145-8. PubMed ID: 12457253
    [Abstract] [Full Text] [Related]

  • 6. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
    Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y.
    Arch Dis Child; 2008 Feb 27; 93(2):142-6. PubMed ID: 17962370
    [Abstract] [Full Text] [Related]

  • 7. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
    Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, Oki I, Ogino H, Schonberger LB, Yanagawa H.
    Pediatr Infect Dis J; 2008 Feb 27; 27(2):155-60. PubMed ID: 18174868
    [Abstract] [Full Text] [Related]

  • 8. Kawasaki disease with severe cardiac sequelae: lessons from recent New Zealand experience.
    Wilson N, Heaton P, Calder L, Nicholson R, Stables S, Gavin R.
    J Paediatr Child Health; 2004 Feb 27; 40(9-10):524-9. PubMed ID: 15367145
    [Abstract] [Full Text] [Related]

  • 9. Persistent monocytosis after intravenous immunoglobulin therapy correlated with the development of coronary artery lesions in patients with Kawasaki disease.
    Kuo HC, Wang CL, Liang CD, Yu HR, Chen HH, Wang L, Yang KD.
    J Microbiol Immunol Infect; 2007 Oct 27; 40(5):395-400. PubMed ID: 17932598
    [Abstract] [Full Text] [Related]

  • 10. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
    Tse SM, Silverman ED, McCrindle BW, Yeung RS.
    J Pediatr; 2002 Apr 27; 140(4):450-5. PubMed ID: 12006960
    [Abstract] [Full Text] [Related]

  • 11. The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease.
    Kuo HC, Yang KD, Liang CD, Bong CN, Yu HR, Wang L, Wang CL.
    Pediatr Allergy Immunol; 2007 Jun 27; 18(4):354-9. PubMed ID: 17584314
    [Abstract] [Full Text] [Related]

  • 12. Treatment of Kawasaki disease using locally product intravenous immunoglobulin.
    Sangtawesin C, Kirawitaya T, Layangkool T, Nawasiri W, Vimolsarawong N.
    J Med Assoc Thai; 2003 Aug 27; 86 Suppl 3():S656-60. PubMed ID: 14700163
    [Abstract] [Full Text] [Related]

  • 13. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children.
    Wooditch AC, Aronoff SC.
    Pediatrics; 2005 Oct 27; 116(4):989-95. PubMed ID: 16199713
    [Abstract] [Full Text] [Related]

  • 14. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease.
    Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S.
    J Pediatr; 2000 Aug 27; 137(2):177-80. PubMed ID: 10931408
    [Abstract] [Full Text] [Related]

  • 15. Management and outcome of intravenous gammaglobulin-resistant Kawasaki disease.
    Sittiwangkul R, Pongprot Y, Silvilairat S, Phornphutkul C.
    Singapore Med J; 2006 Sep 27; 47(9):780-4. PubMed ID: 16924360
    [Abstract] [Full Text] [Related]

  • 16. [Comparison of efficacy among early, conventional and late intravenous gamma globulin treatment of Kawasaki disease].
    Du ZD, Di Z, Du JB, Lu S, Yi JM, Hou AC, Zhou ZS, Ding GF.
    Zhonghua Yi Xue Za Zhi; 2009 Jul 14; 89(26):1841-3. PubMed ID: 19953930
    [Abstract] [Full Text] [Related]

  • 17. Osteoprotegerin serum levels in Kawasaki disease: an additional potential marker in predicting children with coronary artery involvement.
    Simonini G, Masi L, Giani T, Piscitelli E, Cimaz R, Vierucci S, Brandi ML, Falcini F.
    J Rheumatol; 2005 Nov 14; 32(11):2233-8. PubMed ID: 16265708
    [Abstract] [Full Text] [Related]

  • 18. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset.
    Fukunishi M, Kikkawa M, Hamana K, Onodera T, Matsuzaki K, Matsumoto Y, Hara J.
    J Pediatr; 2000 Aug 14; 137(2):172-6. PubMed ID: 10931407
    [Abstract] [Full Text] [Related]

  • 19. Fulfillment of diagnostic criteria in Kawasaki disease.
    Stapp J, Marshall GS.
    South Med J; 2000 Jan 14; 93(1):44-7. PubMed ID: 10653064
    [Abstract] [Full Text] [Related]

  • 20. Atypical and complicated Kawasaki disease in infants. Do we need criteria?
    Joffe A, Kabani A, Jadavji T.
    West J Med; 1995 Apr 14; 162(4):322-7. PubMed ID: 7747497
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.